HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (9) Citing Articles via Google Scholar Google Scholar Articles by Wägner, A. M. Articles by Ordóñez-Llanos, J. Search for Related Content PubMed PubMed Citation Articles by Wägner, A. M. Articles by Ordóñez-Llanos, J. Related Collections Evidence Based Laboratory Medicine and Test Utilization Lipids, Lipoproteins, and Cardiovascular Risk Factors Endocrinology and Metabolism

Inaccuracy of Calculated LDL-Cholesterol in Type 2 Diabetes: Consequences for Patient Risk Classification and Therapeutic Decisions

Departments of
¹ Endocrinology and Nutrition and
² Biochemistry, and
³ Research Institute, Hospital de Sant Pau, 08025 Barcelona, Spain
⁴ Department of Biochemistry and Molecular Biology, Universitat Autònoma, 08025 Barcelona, Spain
^a Department of Biochemistry, Hospital de Sant Pau, Avgda Sant Antoni M^a Claret 167, 08025 Barcelona, Spain; Address correspondence to this author at: fax 34-93-2919196, e-mail 2038@hsp.santpau.es

	Introduction

 
LDL-cholesterol (LDLc) is the main lipid marker in cardiovascular risk estimation and the principal therapeutic target in both diabetic and nondiabetic subjects (1)(2). The designated comparison method for the determination of LDLc, using ultracentrifugation and precipitation, known as "ß-quantification" (3), is cumbersome and time-consuming and requires expensive instrumentation and trained personnel. The Friedewald equation (4) {LDLc = total cholesterol - HDLc - [triglycerides (in mmol/L)/2.17 or triglycerides (in mg/dL)/5]}, the most frequently used method for the calculation of LDLc, assumes that VLDL particles maintain a nearly constant cholesterol:triglyceride ratio. However, this assumption is invalid in the presence of chylomicronemia and increased VLDL or intermediate-density lipoprotein particles (4)(5)(6)(7).

Because diabetic dyslipidemia includes quantitative and qualitative abnormalities in lipoprotein particles, including VLDL and their remnants (8)(9)(10), the use of the Friedewald equation in diabetic patients has been questioned (11)(12)(13). HDL-cholesterol (HDLc), often determined after chemical precipitation of apolipoprotein B (apoB)-containing lipoproteins, has technical drawbacks that could interfere with the accuracy of LDLc calculation (14). New homogeneous, direct methods have improved HDLc determination (15). However, the consequences on patient classification and therapy of using direct, more precise methods for HDLc in the estimation of LDLc by the Friedewald equation have, to our knowledge, not been assessed.

We previously proposed an equation that included total triglycerides and cholesterol, and apoB that was more accurate than the Friedewald equation in estimating LDLc (16). Because diabetic dyslipidemia includes hyperapoB (17), an equation that includes apoB in the estimation of LDLc could be of special interest in these patients. Thus, our aims were to ascertain whether a direct HDLc method increases . . . [Full Text of this Article]

	References

 

The following articles in journals at HighWire Press have cited this article:

				A. M. Wagner, A. Perez, E. Zapico, and J. Ordonez-Llanos Non-HDL Cholesterol and Apolipoprotein B in the Dyslipidemic Classification of Type 2 Diabetic Patients Diabetes Care, July 1, 2003; 26(7): 2048 - 2051. [Abstract] [Full Text] [PDF]

				G. R. Warnick, M. Nauck, and N. Rifai Evolution of Methods for Measurement of HDL-Cholesterol: From Ultracentrifugation to Homogeneous Assays Clin. Chem., September 1, 2001; 47(9): 1579 - 1596. [Abstract] [Full Text] [PDF]